A possible HIV vaccine being developed by Johnson & Johnson didn’t present safety in opposition to the virus in a mid-stage examine, the drugmaker mentioned Tuesday.
J&J plans to finish that examine, which concerned younger girls in sub-Saharan Africa. However researchers will proceed a separate, late-stage trial involving a special composition of the vaccine in males and transgender folks.
The examine in sub-Saharan Africa concerned about 2,600 girls who have been deemed to be at excessive danger of buying HIV, which causes AIDS. Individuals have been randomly chosen to obtain both the vaccine or a placebo and researchers discovered that the vaccine was solely 25 % efficient at stopping HIV.
“HIV is a novel and complicated virus that has lengthy posed unprecedented challenges for vaccine improvement due to its skill to assault, hijack and evade the human immune system,” J&J Chief Scientific Officer Dr. Paul Stoffels mentioned in an announcement.
J&J mentioned its different examine of the potential vaccine is being carried out in Europe and the Americas, the place completely different strains of HIV are circulating.
New Brunswick, New Jersey-based Johnson & Johnson additionally makes one of many three vaccines permitted by US regulators for the prevention of COVID-19. J&J is also creating vaccines for sepsis and respiratory syncytial virus.